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Abstract
 Nearly 40% of deaths after trauma can be attributed to blood loss. It is
well known that early surgical interventions, combined with other
treatment modalities found in the hospital setting, lead to the decreased
morbidity and mortality of trauma patients. However, in an outpatient
setting, treatments for hemorrhage control are extremely limited.
 The purpose of this literature review was to explore tranexamic acid
(TXA) use as an option for hemorrhage control and to determine its effect
on morbidity and mortality in both prehospital and outpatient settings.
TXA is an FDA approved antifibrinolytic that has proven efficacy for
hemorrhage control during many types of surgery and for conditions such
as heavy menstrual bleeding. TXA acts on the normal processes of the
body’s clotting cascade and promotes clotting, while preventing clot
breakdown.
 Data supporting the use of TXA in settings outside of the hospital has
previously been limited. This literature review explored recently
conducted studies that demonstrate the effects on morbidity and mortality
of patients treated with TXA in setting outside of a hospital.
 Evidence from information gathered further promoted the use of TXA in
settings such as, EMS, battlefield medicine, and rural health care facilities
in certain types of trauma. TXA administration reduced the morbidity and
number of deaths from blood loss in the aforementioned settings.
 The findings advocate for the addition of TXA into trauma protocols
shows it will lead to a decrease in the number of deaths due to blood loss
in trauma.

Research Question
 What are the effects on morbidity and mortality of
Tranexamic Acid on trauma patients in the
prehospital setting?

Mechanism of Action
According to McCance and Huether (2010), when injury occurs and the
endothelial cell surface is exposed, the internal and external hemostasis
pathways become activated. The clotting cascade begins and in summary,
the following occurs: platelets bind to the site of injury, fibrinogen and
plasminogen become entrapped in the platelet plug, fibrinogen is cleaved is
turned into the fibrin clot. Eventually, plasminogen is cleaved into plasmin
which breaks apart the clot. It is here where TXA exerts its effect. TXA
competitively binds to receptors on fibrin that would otherwise bind to
plasminogen. The result is less plasminogen in the clot and subsequently
less plasmin to degrade the clot later. Plasmin acts as a key ingredient in
clot breakdown by degrading fibrin resulting in a weaker clot.

(Vu, Schlamp, Wand, Kleine-Deters, Vu, & Tallon, 2013), TXA was
introduced into a Critical Care Paramedic (CCP) flight program.
TXA was used by flight crews a total of 13 times in patients deemed to
have experience major trauma as defined by the research parameters set in
the BCAS Code 99 Trauma Triage Protocols. Indications for administration
of TXA were based on age (at least 16 years or older), trauma, heart rate
greater than 110 bmp, or systolic blood pressure less than 90 mm Hg (Vu et
al., 2013).

 Tranexamic acid is a medication that has been used in hospital settings for over
40 years. It is an antifibrinolytic, which currently, is being used most
frequently to treat postpartum hemorrhage, heavy menstrual bleeding, and perioperatively for surgical procedures. It is widely used in over-the-counter
settings and in hospitals due to it’s safety, efficacy, and inexpensive nature.
However, use in prehospital and trauma settings has been scarcely documented
until recently and has yet to be FDA approved for use in trauma.

 When existing research is compiled and analyzed, several important
conclusions are clearly drawn, yet other questions remain. Mainly, TXA is
shown to be beneficial in trauma patients who were admitted to a hospital, and
TXA reduces mortality if given early (Shakur, Roberts, Bautista, Caballero,
Coats…, 2010). Similarly, positive effects on the reduction of mortality in
combat surgical hospitals in Afghanistan were shown when TXA was used
(Morrison, Dubose, Rasmussen, & Midwinter, 2012). Conversely, TXA will
actually increase mortality if given after a specific amount of time, and in one
study higher incidences of both pulmonary embolism and cardiovascular
embolism were shown (Roberts, Shakur, Coats, Hunt, Balogun, Barnetson, &
Guerriero, 2013).

 The benefits of TXA on preventing death from hemorrhage, depends
on the time between the injury and the start of treatment. Clearly, the
earlier the treatment is initiated, the better the results (Shakur et al.,
2010). Trauma patients presenting to small town emergency rooms,
clinics, rural health facilities, can now be offered a medicine that has
the potential to save their life when it otherwise may not have been
possible.
 The World Health Organization has added TXA to list of essential
medications (Ker et al., 2012). Subsequently, many hospitals, EMS
Pre-hospital use of TXA for trauma
and air ambulance services, and military health care providers have
The Israel Defense Forces’ Initial Experience study (Lipsky, Abramovich,
already begun to implement TXA into their prehospital trauma
Nadler, Feinstein, Shaked, Kreiss, & Glassberg, 2014) explored the effects
protocols. In fact, the Military has designated the use of TXA a Class I
of TXA on all casualty soldiers treated with TXA between December 2011
recommendation in the Tactical Combat Casualty Care guidelines.
and February 2013 (n=40).
Major EMS organizations, such as Hennepin County EMS (HEMS)
Thirty-five of the casualties (88%) were male, with a mean age of 28. In
have developed and are using current TXA protocols. Additionally, the
each case, 1 g of TXA was administered over 5-10 minutes intravenously,
International Trauma Life Support has expressed its consent towards
either by slow push or mixed with crystalloid. Thirty-three received their
the
implementation
of
prehospital
TXA
protocols
(Copeland
et
al.,
TXA within one hour of injury, while the remaining 7 received theirs
2011).
within 2 hours, with the median of elapsed time between injury and
 With the studies reviewed here it is clear to see that the prehospital use
injection of 46 minutes.
Lipsky et al., (2014) concluded that without delaying evacuation, TXA
of TXA in trauma is a safe and effective addition to any current trauma
was administered earlier than it would have been in the hospital, with no
protocol. Not every trauma patient benefits from TXA and there are
reports of adverse outcome when Glasgow Coma Scale scores, vitals,
limitations to its use. However, with appropriate training and careful
procedures performed, and life saving measures used, were compared.
review of the current supporting literature, healthcare providers can
In a related study titled Prehospital Use of Tranexamic Acid for
make an informed medical decision on a medicine that has the
Hemorrhagic Shock in Primary and Secondary Air Medical Evacuation
potential to save a life.

Literature Review

Introduction

 To mediate this lack of research and to allow providers to make informed and
potentially life saving decisions, it is necessary to examine all obtainable
evidence.

Applicability to Clinical
Practice

TXA for trauma
 The Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2
(CRASH 2) study was conducted from 2005 to 2010 and, to date, has been the most
comprehensive examination of the effects of TXA use in trauma patients (Shakur et
al., 2010).
274 hospitals from 40 countries provided the 20,211 participants for the
randomized-placebo controlled study (Shakur et al., 2010). Each subject was an
adult trauma patient with or at risk of significant bleeding, within 8 hours of injury.
This study showed TXA is most beneficial with >30% reduction in all cause
mortality; (p = 0.0035) if given in conjunction with blood transfusion and within
one hour of injury. A greater than 20% reduction in mortality was noted with just
TXA alone.
 The Military Application of Tranexamic Acid in Trauma Emergency Resuscitation
(MATTERs) Study (Morrison, Dubose, Rasmussen, & Midwinter, 2012) was a
retrospective observational study comparing the administration of TXA to no TXA
in patients with combat injuries and who were receiving at least one unit of blood
(n=896). These patients and the data from the study came from a Role 3 Echelon
surgical hospital in southern Afghanistan (similar to a level two trauma center in the
U.S.).
The MATTERs study found that patients who received TXA had a lower
unadjusted mortality (17.4%) when compared to the no TXA group (23.9%; p=.03)
even with the TXA group having been classified as more severely injured with a
mean Injury Severity Score of 25.2 with a standard deviation of 16.6. The No TXA
group had a mean Injury Severity Score of 22.5 with a standard deviation of 18.5;
(p=<0.001).
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Discussion
 In both the MATTERs and CRASH-2 studies, TXA improved
survival.
 A slight increase in thromboembolic events was noted in the TXA
group during the MATTER study. However, this could be
explained by the TXA group being the more severely injured.
 In the Israel Defense Forces’ Initial Experience study and the other
pre-hospital studies that implemented TXA, no adverse effects
were noted. However, the sample sizes were relatively small.
 1 patient treated with TXA out of 67 benefited (nnt=67) from
treatment.
 Future studies should strive for more objective inclusion and
exclusion criteria while using larger sample populations and
objective measurement techniques.
 There are current studies in progress that will further address any
shortcomings: The STAAMP (Study of Tranexamic acid during air
medical prehospital transport trial) and the PATCH (Pre-hospital
Antifibrinolytics for Traumatic Coagulopathy and Hemorrhage)
Study.
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